ASK REDCHAT ANYTHING ABOUT SAGIMET BIOSCIENCES INC.
Sagimet Biosciences Inc. (NASDAQ: SGMT)
Listen to this Section
$7.39
+0.0150
(
+0.20% )
0.0K
Sign up for The Small Stocks Big Money Newsletter and receive free small-cap news and insights.
Clinical Trial Pipeline Stages
| Drug Name |
Stage |
| Denifanstat w/ BevacizumabDetailsGlioblastoma |
Phase 3 |
| Denifanstat (ASC40)DetailsAcne |
Phase 3 |
| DenifanstatDetailsNon-alcoholic steatohepatitis |
Phase 3 |
| DenifanstatDetailsLiver disease |
Phase 1 |
Market Data
|
| Open |
$7.39 |
| Previous Close |
$7.37 |
| Volume |
0.0K |
| Market Cap |
$455.11M |
| Day Range |
$7.34 - $7.62 |
| 52 Week Range |
$4.50 - $11.41 |
| Shares Outstanding |
61.75M |
| Change % |
+0.20% |
| Net Change |
▲ 0.0150 |
| Insider Ownership |
-0.02% |
| Exchange |
NASDAQ |
| Sector | Healthcare |
| Industry | |
| IPO Year | 2023 |
| Country | United States |
| Underwriter | Goldman Sachs, TD Cowen, Piper Sandler, Citizens JMP, more |
Insider Ownership Transactions
Total Amount Purchased:
-6,468,882.00
| Date |
Type |
Amount Purchased |
Purchaser |
| 2024-06-07 |
Sale |
-9279.00 |
Hoelscher Paul W. |
| 2024-05-08 |
Sale |
-587181.00 |
Chauche Thierry |
| 2024-04-03 |
Sale |
-73014.00 |
Walbert Timothy P |
| 2024-04-03 |
Sale |
-73014.00 |
Hoelscher Paul W. |
| 2024-03-28 |
Buy |
12100.00 |
Happel David |
| 2024-01-31 |
Sale |
-850000.00 |
NEW ENTERPRISE ASSOCIATES 13 LP |
| 2024-01-31 |
Sale |
-850000.00 |
SANDELL SCOTT D |
| 2024-01-31 |
Sale |
-850000.00 |
BASKETT FOREST |
| 2024-01-31 |
Sale |
-850000.00 |
NEA Partners 13, Limited Partnership |
| 2024-01-31 |
Sale |
-850000.00 |
KERINS PATRICK J |
SEC Filings
| Form Type |
Description |
Pages |
Date |
| schedule |
Other |
1 |
Nov 14, 2025 |
| 10-q |
Quarterly Reports |
55 |
Nov 13, 2025 |
| 8-k |
8K-related |
66 |
Nov 13, 2025 |
| 4 |
Insider transactions |
1 |
Nov 06, 2025 |
| 8-k |
8K-related |
64 |
Oct 23, 2025 |
| 8-k |
8K-related |
13 |
Aug 22, 2025 |
| 8-k |
8K-related |
15 |
Aug 14, 2025 |
| 8-k |
8K-related |
65 |
Aug 13, 2025 |
| 10-q |
Quarterly Reports |
62 |
Aug 13, 2025 |
| 4 |
Insider transactions |
1 |
Jul 23, 2025 |